Larvol Delta - Immune-checkpoint-inhibition-plus-Bacillus-CalmetteGuerin-BCG-therapy-in-BCGnaive-highrisk-nonmuscleinvasive-bladder-cancer-a160critical-review-in-the-context-of-current-evidence

Imfinzi (durvalumab) - AstraZeneca

Tecentriq (atezolizumab) - Roche

Zumrad (sasanlimab) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42697960

Frank Vom Dorp; Georgios Gakis

Sep 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next